Humoral response to catumaxomab correlates with clinical outcome: Results of the pivotal phase II/III study in patients with malignant ascites

International Journal of Cancer

Volumn 130, Issue 9, 2012, Pages 2195-2203

  Ott, Marion G ^a   Marmé, Frederik ^b   Moldenhauer, Gerhard ^c   Lindhofer, Horst ^d   Hennig, Michael ^a   Spannagl, Rolf ^a   Essing, Mirko M ^a   Linke, Rolf ^a   Seimetz, Diane ^a  

^a Fresenius Biotech   (Germany)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d TRION Pharma GmbH   (Germany)

Author keywords

catumaxomab; clinical outcome; humoral response; malignant ascites; trifunctional antibody

Indexed keywords

CATUMAXOMAB; DRUG ANTIBODY; IMMUNOGLOBULIN G ANTIBODY;

ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ASCITES; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG INFUSION; HUMAN; HUMORAL IMMUNITY; KARNOFSKY PERFORMANCE STATUS; MAJOR CLINICAL STUDY; MALIGNANT ASCITES; MALIGNANT NEOPLASTIC DISEASE; OPEN STUDY; OVARY CANCER; OVERALL SURVIVAL; PARACENTESIS; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; POST HOC ANALYSIS; PRIORITY JOURNAL; PUNCTURE FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; STOMACH CANCER; SURVIVAL RATE; TREATMENT OUTCOME;

ANIMALS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, BISPECIFIC; ANTIBODIES, MONOCLONAL; ASCITES; BIOMARKERS, PHARMACOLOGICAL; FEMALE; HUMANS; IMMUNITY, HUMORAL; IMMUNOTHERAPY; MICE; OVARIAN NEOPLASMS; PARACENTESIS; PERITONEAL NEOPLASMS; RATS; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84855586532     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.26258     Document Type: Review

References (26)

1. Ruf P, Gires O, Jäger M, Fellinger K, Atz J, Lindhofer H,. Characterisation of the new EpCAM-specific antibody HO-3: implications for trifunctional antibody immunotherapy of cancer. Br J Cancer 2007; 97: 315-21.
2. Zeidler R, Reisbach G, Wollenberg B, Lang S, Chaubal S, Schmitt B, Lindhofer H,. Simultaneous activation of T-cells and accessory cells by a new class of intact bispecific antibody results in efficient tumour cell killing. J Immunol 1999; 163: 1246-52.
3. Zeidler R, Mysliwietz J, Csánady M, Walz A, Ziegler I, Schmitt B, Wollenberg B, Lindhofer H,. The Fc-region of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumour cells. Br J Cancer 2000; 83: 261-6.
4. Seimetz D, Lindhofer H, Bokemeyer C,. Development and approval of the trifunctional antibody catumaxomab (anti-EpCAMxanti-CD3) as a targeted cancer immunotherapy. Cancer Treat Rev 2010; 36: 458-67.
5. Ruf P, Lindhofer H,. Induction of a long-lasting antitumor immunity by a trifunctional bispecific antibody. Blood 2001; 98: 2526-34.
6. Morecki S, Lindhofer H, Yacovlev E, Gelfand Y, Ruf P, Slavin S,. Induction of long-lasting antitumor immunity by concomitant cell therapy with allogeneic lymphocytes and trifunctional bispecific antibody. Exp Hematol 2008; 36: 997-1003.
7. Ströhlein MA, Siegel R, Jäger M, Lindhofer H, Jauch KW, Heiss MM,. Induction of anti-tumor immunity by trifunctional antibodies in patients with peritoneal carcinomatosis. J Exp Clin Cancer Res 2009; 28: 18.
8. Heiss MM, Murawa P, Koralewski P, Kutarska E, Kolesnik OO, Ivanchenko VV, Dudnichenko AS, Aleknaviciene B, Razbadauskas A, Gore M, Ganea-Motan E, Ciuleanu T, et al. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase II/III trial. Int J Cancer 2010; 127: 2209-21.
9. DeNardo GL, Bradt BM, Mirick GR, DeNardo SJ,. Human antiglobulin response to foreign antibodies: therapeutic benefit? Cancer Immunol Immunother 2003; 52: 309-16.
10. Marmé A, Strauss G, Bastert G, Grischke EM, Moldenhauer G,. Intraperitoneal bispecific antibody (HEA125xOKT3) therapy inhibits malignant ascites production in advanced ovarian carcinoma. Int J Cancer 2002; 101: 183-9.
11. Mirick GR, Bradt BM, Denardo SJ, Denardo GL,. A review of human anti-globulin antibody (HAGA, HAMA, HACA, HAHA) responses to monoclonal antibodies. Not four letter words. Q J Nucl Med Mol Imaging 2004; 48: 251-7.
12. Azinovic I, DeNardo GL, Lamborn KR, Mirick G, Goldstein D, Bradt BM, DeNardo SJ,. Survival benefit associated with human anti-mouse antibody (HAMA) in patients with B-cell malignancies. Cancer Immunol Immunother 2006; 55: 1451-8.
13. Cheung NK, Kushner BH, Cheung IY, Kramer K, Canete A, Gerald W, Bonilla MA, Finn R, Yeh SJ, Larson SM,. Anti-G(D2) antibody treatment of minimal residual stage 4 neuroblastoma diagnosed at more than 1 year of age. J Clin Oncol 1998; 16: 3053-60.
14. Cheung N-KV, Guo HF, Heller G, Cheung IY,. Induction of Ab3 and Ab3†antibody was associated with long-term survival after anti-G(D2) antibody therapy of stage 4 neuroblastoma. Clin Cancer Res 2000; 6: 2653-60.
15. DeNardo GL, Mirick GR, Kroger LA, Bradt BM, Lamborn KR, DeNardo SJ,. Characterization of human IgG antimouse antibody in patients with B-cell malignancies. Clin Cancer Res 2003; 9: 4013S-21S.
16. Lanzavecchia A, Abrignani S, Scheidegger D, Obrist R, Dörken B, Moldenhauer G,. Antibodies as antigens. The use of mouse monoclonal antibodies to focus human T cells against selected targets. J Exp Med 1988; 167: 345-52.
17. Miotti S, Negri DR, Valota O, Calabrese M, Bolhuis RL, Gratama JW, Colnaghi MI, Canevari S,. Level of anti-mouse-antibody response induced by bi-specific monoclonal antibody OC/TR in ovarian-carcinoma patients is associated with longer survival. Int J Cancer 1999; 84: 62-8.
18. Belau A, Pfisterer J, Wimberger P, Kurzeder C, Du Bois A, Sehouli J, Loibl S, Burchardi N, Vergote I, Wagner U,. Randomized, multicenter, two-dose level, open-label, phase IIa study with the intraperitoneally infused trifunctional bispecific antibody catumaxomab (anti-EpCAM Ã - anti-CD3) to select the better dose level in platinum refractory epithelial ovarian cancer patients. J Clin Oncol 2007; 25:Abstract 5556.
19. Pietzner K, Linke RG, Jäger M, Lindhofer H, Friccius-Quecke H, Chen F, Braicu EI, Oskay-Ã-zcelik G, Sehouli J,. Phase II clinical trial to evaluate the safety of repeated cycles of intraperitoneal catumaxomab for the treatment of malignant ascites (SECIMAS). J Clin Oncol 2010; 28:Abstract TPS155.
20. Berek J, Taylor P, McGuire W, Smith LM, Schultes B, Nicodemus CF,. Oregovomab maintenance monoimmunotherapy does not improve outcomes in advanced ovarian cancer. J Clin Oncol 2009; 27: 418-25.
21. Grant SC, Kris MG, Houghton AN, Chapman PB,. Long survival of patients with small cell lung cancer after adjuvant treatment with the anti-idiotypic antibody BEC2 plus Bacillus Calmette-Guérin. Clin Cancer Res 1999; 5: 1319-23.
22. Wagner U, Köhler S, Reinartz S, Giffels P, Huober J, Renke K, Schlebusch H, Biersack HJ, Möbus V, Kreienberg R, Bauknecht T, Krebs D, et al. Immunological consolidation of ovarian carcinoma recurrences with monoclonal anti-idiotype antibody ACA125: immune responses and survival in palliative treatment. Clin Cancer Res 2001; 7: 1154-62.
23. Bournazos S, Woof JM, Hart SP, Dransfield I,. Functional and clinical consequences of Fc receptor polymorphic and copy number variants. Clin Exp Immunol 2009; 157: 244-54.
24. Weiner LM, Dhodapkar MV, Ferrone S,. Monoclonal antibodies for cancer immunotherapy. Lancet 2009; 373: 1033-40.
25. Getts DR, Getts MT, McCarthy DP, Chastain EM, Miller SD,. Have we overestimated the benefit of human(ized) antibodies? MAbs 2010; 2: 682-94.
26. Dettmar K, Atz J, Lindemann C, Schroeder P, Eberhardt A, Kluge M,. Establishment of preclinical models to identify clinically useful combinations of trifunctional antibodies with chemotherapy. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research, April 17-21, Washington, DC, 2010. 844-5 (Abstract 3481).